As far back as 2007, triple therapy for wet (neovascular) age-related macular degeneration (AMD) was shown to be superior to mono therapy (intraocular injection of a single anti-VEGF drug).* And now, a study described in a recent online publication of the peer-reviewed monthly, International Journal of Retina and Vitreous, found that triple therapy supplemented with [Read More]
Category: Research and Developments
Delayed Dark Adaptation Predicts Onset of Dry AMD
A recent study* at the University of Alabama has found that measurement of the time it takes older adults’ eyes to adapt to the dark can predict onset of dry age-related macular degeneration (dAMD). Using a computerized dark adaptometer, 325 persons with healthy eyes were each subjected to a flash of light in one eye, [Read More]
X-82 Oral Medication May Reduce Number of Intravitreal Injections for Wet AMD
No cure yet exists for wet AMD, but three FDA-approved therapies are slowing the progress of wet AMD and reducing the amount of vision loss. These treatments are ranibizumab (Lucentis), aflibercept (Eylea), and off-label bevacizumab (Avastin). These medications are highly successful, but they must be injected directly into the eye, and the treatment often needs [Read More]
Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy
(Updated 12/5/2017) On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian [Read More]
RXI-109 May Reduce Retinal Scarring
New drug silences connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair. by Dan Roberts (Updated August 2018) One of the most serious causes of vision loss is development of scar tissue on, in, or under the retina. People can develop retinal scarring from severe myopia, ocular histoplasmosis syndrome, [Read More]